氨基白血受体1调节人类视网膜细胞中的细胞葡萄糖水平
Andreas Koller1, Susanne Maria Brunner1, Julia Preishuber-Pflügl1
1Research Program for Experimental Ophthalmology and Glaucoma Research, Department of Ophthalmology and Optometry, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
Molecular vision
|November 27, 2025
概括
抑制cysteinyl leukotriene受体1 (CysLTR1) 对视网膜细胞葡萄糖水平产生影响. 它的活性复杂,在高葡萄糖下显示逆效应,这表明它是糖尿病和视网膜病变的潜在治疗标.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- 氨基白血受体1 (CysLTR1) 是一种与G蛋白结合的受体,在炎症和胰岛素分泌中具有已知的作用.
- 在早期糖尿病视网膜病变中,CysLTR1抑制已经显示出增加视网膜细胞存活率的前景.
- 在视网膜血管细胞内调节葡萄糖水平的CysLTR1的作用仍然在很大程度上未被探索.
研究的目的:
- 研究CysLTR1抑制对视网膜内皮细胞 (ECs),皮细胞 (PCs) 和ARPE-19细胞中的细胞内葡萄糖水平的影响.
- 确定CysLTR1在标准条件和高葡萄糖条件下如何调节葡萄糖水平.
- 评估CysLTR1抑制对视网膜细胞单层完整性的影响.
主要方法:
- 人类视网膜EC,PC和ARPE-19细胞在标准和高葡萄糖条件下进行培养.
- 细胞接受了CysLTR1抗体 (蒙特卢卡斯特,扎菲尔卢卡斯特) 的治疗,持续时间不同.
- 分析了CysLTR1表达,CysLT分泌,细胞内葡萄糖水平,细胞活力和单层电阻.
主要成果:
- 在标准葡萄糖条件下,CysLTR1抑制在视网膜细胞中增加了细胞内葡萄糖.
- 在高葡萄糖条件下,CysLTR1抑制最初降低,然后在ARPE-19细胞中增加细胞内葡萄糖.
- 抑制CysLTR1影响了视网膜细胞单层的紧密性,根据葡萄糖度有不同的影响.
结论:
- CysLTR1的活动直接影响视网膜细胞中的细胞葡萄糖水平,支持其作为2型糖尿病和糖尿病视网膜病变治疗点的潜力.
- CysLTR1对葡萄糖水平的调节作用是复杂的,在急性代谢压力下可以逆转.
- 需要进一步的研究,以充分阐明CysLTR1在视网膜环境中的葡萄糖代谢中的复杂作用.
相关概念视频
Hormones Regulating Blood Glucose
6.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Cell Specific Gene Expression
16.2K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.2K
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Glucose Absorption Into the Small Intestine
34.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.7K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820


